Heron Therapeutics

May 01, 2019

No news equals bad news for Nabriva and Heron

Manufacturing issues prompt the US regulator to knock back projects from Nabriva and Heron Therapeutics, both of which insist that the problems are easily solvable.

March 28, 2019

Go or no go? Abbvie, Glaxo and Heron await FDA verdicts

Notable US regulatory decisions due in April feature a major pipeline hope from Abbvie, a non-opioid pain medication from Heron and Glaxo’s two-pill HIV regimen.

October 08, 2018

US opioid crisis package nears enactment

Medicare is to review ways to encourage use of non-addictive pain relievers, but Heron Therapeutics will miss out on extension of a special payment provision.

June 27, 2018